Aardvark Therapeutics (AARD) News
NASDAQ: AARDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AARD news summary
We found 4 recent headlines mentioning Aardvark Therapeutics (AARD): 4 in the past week and 4 in the past 30 days, most often from PR Newswire, Business Insider, GlobeNewswire. For price context, AARD is up 1.06% at $4.76. The most recent story, "AARD FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD", was published by Business Insider on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Aardvark Therapeutics headlines
- AARD FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD<img src="https://api.newsfilecorp.com/newsinfo/318217/208" id="208" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;">New York, New York--(Newsfile Corp. - October 9, 2026) -…Business Insider
- AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 8, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark…PR Newswire
- Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of DirectorsBrings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/RocheGlobeNewswire
- AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, A TOP RANKED LAW FIRM, Encourages Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 DeadlineNEW YORK, Oct. 7, 2026 /PRNewswire/ -- AARDVARK THERAPEUTICS SECURITIES CLASS ACTION: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ:…PR NewswireAARD, NDAQ